These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16335863)

  • 1. Safety of potent gastric acid inhibition.
    Martín de Argila C
    Drugs; 2005; 65 Suppl 1():97-104. PubMed ID: 16335863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimising acid inhibition treatment.
    Gomollón F; Calvet X
    Drugs; 2005; 65 Suppl 1():25-33. PubMed ID: 16335855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacological approach to gastric acid inhibition.
    Esplugues JV
    Drugs; 2005; 65 Suppl 1():7-12. PubMed ID: 16335853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal use of proton pump inhibitors for treating acid peptic diseases in primary care.
    Tack J; Louis E; Persy V; Urbain D
    Acta Gastroenterol Belg; 2013 Dec; 76(4):393-402. PubMed ID: 24592542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
    Metz DC
    Digestion; 2000; 62(2-3):73-81. PubMed ID: 11025353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Are proton pump inhibitors safe?].
    Creutzfeldt W
    Internist (Berl); 1994 Dec; 35(12):1137-46. PubMed ID: 7883517
    [No Abstract]   [Full Text] [Related]  

  • 8. What is potent acid inhibition, and how can it be achieved?
    Calvet X; Gomollón F
    Drugs; 2005; 65 Suppl 1():13-23. PubMed ID: 16335854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of gastric acid secretion and therapeutic results: is there any correlation?
    Corinaldesi R; Ghidini C; Ricci Maccarini M; Santaguida P; Fratesi E; Barbara G; Stanghellini V
    Ital J Gastroenterol; 1990; 22 Suppl 1():2-4. PubMed ID: 1983421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic drug interaction profiles of proton pump inhibitors.
    Blume H; Donath F; Warnke A; Schug BS
    Drug Saf; 2006; 29(9):769-84. PubMed ID: 16944963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase.
    McArthur KE; Jensen RT; Gardner JD
    Annu Rev Med; 1986; 37():97-105. PubMed ID: 3010811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations for long-term use of proton-pump inhibitors.
    Garnett WR
    Am J Health Syst Pharm; 1998 Nov; 55(21):2268-79. PubMed ID: 9825878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitor side effects and drug interactions: much ado about nothing?
    Madanick RD
    Cleve Clin J Med; 2011 Jan; 78(1):39-49. PubMed ID: 21199906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations.
    Devault KR
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):197-205. PubMed ID: 19072410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a dark side to long-term proton pump inhibitor therapy?
    Nealis TB; Howden CW
    Am J Ther; 2008; 15(6):536-42. PubMed ID: 19127138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitors and acid-related diseases.
    Sachs G
    Pharmacotherapy; 1997; 17(1):22-37. PubMed ID: 9017763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks versus benefits of long-term proton pump inhibitor therapy in the elderly.
    Schuler A
    Geriatr Nurs; 2007; 28(4):225-9. PubMed ID: 17936957
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects.
    Jiao HW; Sun LN; Li YQ; Yu L; Zhang HW; Wang MF; Yu LY; Yuan ZQ; Xie LJ; Chen J; Meng L; Zhang XH; Wang YQ
    Eur J Clin Pharmacol; 2018 Mar; 74(3):257-265. PubMed ID: 29167917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
    Jensen RT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.